Empagliflozin
Brand name: Jardiance
Rank #3 of 500 drugs by total cost
$3.58B
Total Cost
3,334,784
Total Claims
$3.58B
Total Cost
71,367
Prescribers
$1,074
Cost per Claim
637,917
Beneficiaries
6,148,290
30-Day Fills
$50K
Avg Cost/Provider
47
Avg Claims/Provider
About Empagliflozin
Empagliflozin (sold as Jardiance) was prescribed 3,334,784 times by 71,367 Medicare Part D providers in 2023, costing the program $3.58B. At $1,074 per claim, this is a high-cost medication.
💰 This drug alone accounts for 1.3% of all Medicare Part D drug spending.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 1 | Apixaban (Eliquis) | $7.75B | 8,995,930 |
| 2 | Semaglutide (Ozempic) | $4.30B | 3,193,643 |
| 3 | Empagliflozin (Jardiance) | $3.58B | 3,334,784 |
| 4 | Dulaglutide (Trulicity) | $2.99B | 2,175,100 |
| 5 | Rivaroxaban (Xarelto) | $2.45B | 2,628,123 |
| 6 | Adalimumab (Humira(Cf) Pen) | $2.17B | 240,925 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology